[1] Vane J R, Botting R M. New insights into the mode of action of anti-inflammatory drugs[J].Inflamm Res,1995, 44:1-10.
[2] Jaradat N. Phytochemical profile and in vitro antioxidant, antimicrobial, vital physiological enzymes inhibitory and cytotoxic effects of artemisia jordanica leaves essential oil from palestine[J]. Molecules, 2021, 26(9): 2831.
[3] Berbecka M, Forma A, Baj J, et al. A systematic review of the cyclooxygenase-2 (COX-2) expression in rectal cancer patients treated with preoperative radiotherapy or radiochemotherapy[J]. J Clin Med, 2021, 10(19): 4443.
[4] 张 欣, 刘 峰, 姬 敏. 塞来昔布治疗类风湿关节炎疗效与安全性分析[J].社区医学杂志, 2020, 18(6):425-428.
[5] 梁增冰,陈家良,覃小霞.塞来昔布治疗类风湿关节炎的临床疗效和用药安全性分析[J].中国社区医师,2021,37(28):36-37.
[6] 叶淑屏.艾瑞昔布治疗膝骨关节炎的有效性和安全性[J].哈尔滨医药,2020,40(6):515-516.
[7] Ishi Y, Harada T, Kameda H, et al. Variations and natural history of primary intraparenchymal lesions associated with neurofibromatosis type 2[J]. Neuroradiology, 2022, 64(2):393-396.
[8] 杨冰倩, 华清泉, 陈惠东,等. 神经纤维瘤病2型的治疗进展[J]. 中国医师杂志, 2020, 22(8):1121-1125.
[9] Guerrant W, Kota S, Troutman S, et al. YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis[J]. Cancer Res, 2016,76(12):3507-3519.
[10] Birzu C, French P J, Caccese M, et al. Recurrent glioblastoma: from molecular landscape to new treatment perspectives[J]. Cancers, 2021, 13(1):47.
[11] 孙伟子, 吴求吉, 柳 麒,等. 胶质母细胞瘤治疗研究进展[J]. 中华实用诊断与治疗杂志, 2019, 33(10):1037-1040.
[12] Shahcheraghi S H, Tchokonte-Nana V, Lotfi M, et al. Wnt/beta-catenin and PI3K/Akt/mTOR signaling pathways in glioblastoma: two main targets for drug design: a review[J]. Curr Pharm Design, 2020, 26(15):1729-1741.
[13] Liu X, Gao Q, Zhao N, et al. Sohlh1 suppresses glioblastoma cell proliferation, migration and invasion by inhibition of Wnt/β-catenin signaling[J]. Mol Carcin, 2018,57(4):494-502.
[14] Majchrzak C A, Misiorek J O, Kruhlenia N, et al. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β- catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells[J]. BMC Cancer, 2021, 21(493):1-18.
[15] Alqahtani A M, Chidambaram K, Pino-Figueroa A, et al. Curcumin-celecoxib: a synergistic and rationale combination chemotherapy for breast cancer[J]. Eur Rev Med Pharmaco Sci, 2021, 25(4): 1916-1927.
[16] Thijs R D, Surges R, O'Brien T J, et al. Epilepsy in adults[J]. The Lancet, 2019, 393(10172): 689-701.
[17] Leguia M G, Andrzejak R G, Rummel C, et al. Seizure cycles in focal epilepsy[J]. JAMA Neurol,2021,78(4):454-463.
[18] 彭安娇, 何时旭, 朱 曦,等. 炎症在癫痫发病机制中的研究进展[J]. 癫痫杂志, 2018, 4(1):36-39.
[19] Sanz P, Garcia-Gimeno M A. Reactive glia inflammatory signaling pathways and epilepsy[J]. Int J Mol Sci, 2020, 21(11):4096.
[20] Citraro R, Leo A, Marra R, et al. Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats[J]. Brain Res Bull, 2015, 113:1-7.
[21] Katyal J, Kumar H, Gupta Y K. Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment[J]. Epilepsy Behav, 2015, 44:98-103.
[22] Alsaegh H, Eweis H, Kamel F, et al. Celecoxib decrease seizures susceptibility in a rat model of inflammation by inhibiting HMGB1 translocation[J]. Pharmaceuticals, 2021, 14(4):380.
[23] Polascheck N, Bankstahl M, LScher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy[J]. Exp Neurol, 2010, 224(1):219-233.
[24] Chan P C, Liao M T, Hsieh P S. The dualistic effect of COX-2-mediated signaling in obesity and insulin resistance[J]. Int J Mol Sci, 2019, 20(13):3115.
[25] Chan P C, Wu T N, Chen Y C, et al. Targeted inhibition of CD74 attenuates adipose COX-2-MIF-mediated M1 macrophage polarization and retards obesity-related adipose tissue inflammation and insulin resistance[J]. Clin Sci, 2018, 132(14):1581-1596.
[26] Rasha F, Ramalingam L, Gollahon L, et al. Mechanisms linking the renin-angiotensin system, obesity, and breast cancer[J]. Endocr Cancer, 2019, 26(12): 653-672.
[27] Ekor M, Owusu P E, Obese E, et al. Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia[J]. PloS One, 2021, 16(8): e0247735.
[28] Lula J, Paula A D, Guimaraes A, et al. Cox enzyme inhibitor, celecoxib, reduces steatosis and liver lipogenesis in high-fat fed mice[J]. Curr Enzyme Inhibit, 2018, 14(2):114-119.
[29] Lebedeva E S, Kuzubova N N, Titova O N, et al. Effect of cyclooxygenase-2 inhibition on lung inflammation and hypoxia-inducible factor-1 signalling in COPD model[J].Eur Respir J,2017, 50:3926.
[30] Azmoonfar R, Amini P, Saffar H, et al. Celecoxib a selective COX-2 inhibitor mitigates fibrosis but not pneumonitis following lung irradiation: a histopathological study[J]. Curr Drug Ther, 2020, 15(4):351-357.
[31] Jin H. Imrecoxib inhibits paraquat-induced pulmonary fibrosis through the NF-κB/snail signaling pathway[J]. Comput Math Method M, 2020, 2020: 1-9.
[32] Majd M, Saunders E, Engeland C G. Inflammation and the dimensions of depression: a review[J]. Front Neuroendocrinol, 2019, 56:100800.
[33] Leonard B E. Inflammation and depression: a causal or coincidental link to the pathophysiology?[J]. Acta Neuropsychiatr, 2017, 30(1):1-16.
[34] Dooley L N, Kuhlman K R, Robles T F, et al. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation[J]. Neurosci Biobehav Res, 2018, 94: 219-237.
[35] Felger J C. Role of inflammation in depression and treatment implications[M].Antidepressants Springer:Cham, 2018: 255-286.,
[36] 刘至阳,苏文君,严雯婕,等. 抑郁症炎症机制研究进展[J]. 临床军医杂志, 2020, 48(12):129-132.
[37] Faridhosseini F, Sadeghi R, Farid L, et al. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials[J]. Hum Psychopharm Clin, 2014, 29(3):216-223.
[38] Kurhe Y, Mahesh R, Gupta D. Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an approach using behavioral tests[J]. Neurochem Res, 2014, 39(7):1395-1402.
[39] Na K S, Lee K J, Lee J S, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis[J]. Prog Neuro Psychoph, 2014, 48:79-85.
[40] 李明轩,辛 辰,王忠琼.塞来昔布对急性出血坏死性胰腺炎炎症介质的影响[J].现代医药卫生,2018,34(13):1968-1971.
[41] Huang Z, Ma X, Jia X, et al. Prevention of severe acute pancreatitis with cyclooxygenase-2 inhibitors: a randomized controlled clinical trial[J]. Am J Gastroenterol, 2020, 115(3): 473.
[42] 王 玥, 于 嵩, 王 旭. COX-2特异性抑制剂罗非昔布对阿尔茨海默病Aβ沉积的影响[J]. 天然产物研究与开发, 2018, 30(6):6.
[43] 吴建兵, 黄张建, 张奕华. 一氧化氮供体型心脑血管药物研究的实践与思考[J]. 中国药科大学学报, 2021,52(2):129-143.
[44] 龚震宇, 刘顺财.一氧化氮与肠道炎症关系的研究进展[J]. 现代消化及介入诊疗, 2020, 25(1):136-138.
[45] Wallace J L, Soldato P D. The therapeutic potential of NO-NSAIDs[J]. Fund Clin Pharmacol, 2003, 17(1): 11-20.
[46] Bakr R B, Abdelall E, Abdellatif K,et al. Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents[J]. Curr Top Med Chem, 2017, 17(8): 941-955.
[47] Bechmann N, Kniess T, Köckerling M, et al. Novel (pyrazolyl) benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors[J]. Bioorg Med Chem Lett,2015, 25(16): 3295-3300.
[48] Consalvi S, Poce G, Ragno R, et al. A series of COX-2 inhibitors endowed with NO-releasing properties: synthesis, biological evaluation, and docking analysis[J]. Chem Med Chem, 2016, 11(16): 1804-1811.
[49] Almansa C, Merce R, Tesson N, et al. Co-crystal of tramadol hydrochloride-celecoxib (CTC): a novel API-API co-crystal for the treatment of pain[J]. Cryst Growth Des, 2017, 17(4): 1884-1892.